4.6 Letter

Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort

Related references

Note: Only part of the references are listed.
Letter Hematology

Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease

Fleur Cohen Aubart et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

Review Oncology

Histiocytoses: emerging neoplasia behind inflammation

Julien Haroche et al.

LANCET ONCOLOGY (2017)

Article Oncology

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Eli L. Diamond et al.

CANCER DISCOVERY (2016)

Article Clinical Neurology

Complete remission of critical neurohistiocytosis by vemurafenib

Philipp Euskirchen et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)

Article Hematology

Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease

Jean-Francois Emile et al.

BLOOD (2014)

Article Rheumatology

Erdheim-Chester Disease

Julien Haroche et al.

CURRENT RHEUMATOLOGY REPORTS (2014)